晚期结直肠癌的医学治疗进展。

Roczniki Akademii Medycznej w Bialymstoku (1995) Pub Date : 2005-01-01

V Sultan-Amar, E Fabre-Guillevin, P Piedbois

{"title":"晚期结直肠癌的医学治疗进展。","authors":"V Sultan-Amar, E Fabre-Guillevin, P Piedbois","doi":"","DOIUrl":null,"url":null,"abstract":"In the last 2 decades, major progresses have been made in the management of patients with advanced colorectal cancer (ACC). The modulation of 5-fluorouracil (5-FU) by folinic acid (LV), followed by the introduction of irinotecan and oxaliplatin have significantly improved the outcome of these patients. New strategies consist of oral fluoropyrimidines, and of targeted agents to inhibit cancer signalisation.","PeriodicalId":79372,"journal":{"name":"Roczniki Akademii Medycznej w Bialymstoku (1995)","volume":"50 ","pages":"97-100"},"PeriodicalIF":0.0000,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progresses in the medical treatment of advanced colorectal cancer.\",\"authors\":\"V Sultan-Amar, E Fabre-Guillevin, P Piedbois\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the last 2 decades, major progresses have been made in the management of patients with advanced colorectal cancer (ACC). The modulation of 5-fluorouracil (5-FU) by folinic acid (LV), followed by the introduction of irinotecan and oxaliplatin have significantly improved the outcome of these patients. New strategies consist of oral fluoropyrimidines, and of targeted agents to inhibit cancer signalisation.\",\"PeriodicalId\":79372,\"journal\":{\"name\":\"Roczniki Akademii Medycznej w Bialymstoku (1995)\",\"volume\":\"50 \",\"pages\":\"97-100\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Roczniki Akademii Medycznej w Bialymstoku (1995)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Roczniki Akademii Medycznej w Bialymstoku (1995)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在过去的二十年中，晚期结直肠癌(ACC)患者的治疗取得了重大进展。用亚叶酸(LV)调节5-氟尿嘧啶(5-FU)，随后引入伊立替康和奥沙利铂，显著改善了这些患者的预后。新的策略包括口服氟嘧啶和靶向药物来抑制癌症信号。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Progresses in the medical treatment of advanced colorectal cancer.

In the last 2 decades, major progresses have been made in the management of patients with advanced colorectal cancer (ACC). The modulation of 5-fluorouracil (5-FU) by folinic acid (LV), followed by the introduction of irinotecan and oxaliplatin have significantly improved the outcome of these patients. New strategies consist of oral fluoropyrimidines, and of targeted agents to inhibit cancer signalisation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Roczniki Akademii Medycznej w Bialymstoku (1995)

自引率

0.00%

发文量